ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0296

The Impact of Delayed Primary Sjögren’s Syndrome Diagnosis on Patient Outcomes: A Real-World Survey in the US

Briana Ndife1, Sophie Barlow2, Megan Hughes2 and Nicola Booth2, 1Novartis, East Hanover, NJ, 2Adelphi Real World, Bollington, United Kingdom

Meeting: ACR Convergence 2021

Keywords: Patient reported outcomes, Real World Evidence, Sjögren's syndrome

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 6, 2021

Title: Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)

Session Type: Poster Session A

Session Time: 8:30AM-10:30AM

Background/Purpose: Diagnosis of primary Sjögren’s syndrome (pSS) is challenging due to the disease’s phenotypic heterogeneity. pSS patients frequently experience a prolonged period between symptomatic onset and diagnosis, hypothesised to prove detrimental to patient outcomes. The objective of this study was to describe the impact of delayed diagnosis on disease severity and patient outcomes in patients with pSS.

Methods: Data were drawn from the Adelphi Primary Sjögren’s Syndrome (pSS) Disease Specific Programme™, a real-world point-in-time survey of rheumatologists and their consulting pSS patients in the United States. Physicians provided data on patient demographics and clinical characteristics. Patients self-completed patient-reported outcome (PRO) tools; including the EuroQol 5-dimension 5-level utility score (EQ-5D), EuroQol visual analogue scale (EQ VAS), Work Productivity and Activity Impairment Index questionnaire (WPAI), and the Functional Assessment of Chronic Illness Therapy – Fatigue (FACIT-F). EULAR Sjögren’s Syndrome Disease Activity Index (ESSDAI) and EULAR Sjögren’s Syndrome Patient Reported Index (ESSPRI) proxy scores were calculated by assigning scores to physician-perceived severity in each of the associated domains. Patients were compared according to the time between onset of pSS symptoms and diagnosis (< 3 months, 3-6 months, 6-12 months, and >12 months). Analysis of variance and Kruskall-Wallis tests were used to examine the impact of delayed diagnosis on ESSDAI, ESSPRI and PRO measures, and Mann-Whitney U-test for physician-perceived current severity using < 3 months as the reference group.

Results: 71 rheumatologists provided information for 276 pSS patients: mean age 52.3 years, 89.1% female and average time since diagnosis 51.6 months (Table 1). Of these patients, 29.3% were diagnosed within 3 months of the onset of pSS symptoms, 20.3% 3-6 months, 17.8% 6-12 months and 32.6% >12 months, with a mean (SD) of 27.5 (68.2) months from the onset of symptoms to diagnosis. Comparative analyses showed that there were significant differences (< 0.05) in EQ-5D utility score, EQ-5D VAS, FACIT-F, proxy ESSPRI scores and physician reported severity between patients with differing time to diagnosis (Table 2), assessed at the time of consultation. Relationships between diagnosis duration and WPAI scores were not statistically significant.

Conclusion: Delayed diagnosis of pSS is associated with poorer patient outcomes; including worsening PRO scores, and ESSPRI scores. pSS diagnosis periods could likely be attenuated by increasing disease awareness amongst physicians; thus improving patient outcomes in pSS.

Table 1: pSS patient demographics and clinical characteristics by time from onset of symptoms to diagnosis

Table 2: Comparison of patient-reported outcomes, ESSDAI proxy and ESSPRI proxy scores by time from onset of symptoms to diagnosis


Disclosures: B. Ndife, Novartis, 3, 11; S. Barlow, None; M. Hughes, None; N. Booth, None.

To cite this abstract in AMA style:

Ndife B, Barlow S, Hughes M, Booth N. The Impact of Delayed Primary Sjögren’s Syndrome Diagnosis on Patient Outcomes: A Real-World Survey in the US [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/the-impact-of-delayed-primary-sjogrens-syndrome-diagnosis-on-patient-outcomes-a-real-world-survey-in-the-us/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-impact-of-delayed-primary-sjogrens-syndrome-diagnosis-on-patient-outcomes-a-real-world-survey-in-the-us/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology